Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

This study is for men who have prostate cancer that hasn't spread beyond the prostate or nearby lymph nodes, and who are planning to have surgery to remove their prostate. Your doctors will need to confirm you have prostate cancer based on a biopsy, and it should be an 'intermediate-' or 'high-risk' type, which they will explain to you.

To be considered, you'll need to have had specific scans recently, like a PSMA-PET scan, to help determine the extent of your cancer. Your general health and ability to carry out daily activities will also be assessed, usually by a simple performance score.

You won't be able to join if you've already had treatment for your prostate cancer (though there might be a small exception if you've recently had a specific type of hormone therapy). Also, if your cancer has spread to other parts of your body, or if you have certain other serious health conditions like an active infection or an autoimmune disease that permanently affects your immune system, you won't be able to take part.

If you decide to take part in this study, you will receive either xaluritamig on its own or xaluritamig combined with a GnRH antagonist, before your planned prostatectomy surgery. The study involves regular visits to the hospital for checks, which may include physical exams, blood tests, and scans. These visits will monitor how you are responding to the medication and check for any side effects. After your surgery, you will continue to have follow-up appointments to monitor your recovery and the long-term effects of the treatment. The total duration of your participation, including the treatment period and follow-up, will be explained in detail by the study team, but typically involves several months of treatment followed by ongoing checks.